Furthermore, the NtB administration route of active pharmaceutical ingredients (APIs) for neurodegenerative diseases such as AD has been widely implemented, whereas multiple clinical trials (i.e., NCT03857321) with i.n.-administered insulin (Humulin®) have been conducted [226]. The gene discussed is INS; the disease is Alzheimer disease.